Company ProfilePremium

Chong Kun Dang Holdings Corp.

Company Profile Analysis

Ticker: 001630.KS종근당홀딩스

ESOMAR 23 Corporate BadgeISO Certifications Badge
Chong Kun Dang Holdings Corp. - Company showcase

Year Founded & Workforce

1941

575 Employees

Chong Kun Dang Holdings Corp. logo

Chong Kun Dang Holdings Corp. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Chong Kun Dang Holdings Corp. Overview

The listing has not moved and the company has not changed its name since 2013.

Identification Table

ItemDetail
Legal nameChong Kun Dang Holdings Corp. (㈜종근당홀딩스)
Former nameChong Kun Dang Corp. (㈜종근당). The listed entity became the holding company and was renamed when the operating business was split off in November 2013.
Founding7 May 1941 (Gungbon Pharmacy, the predecessor business), per company website
IncorporationRegistered as a stock company in January 1956. Incorporated in the Republic of Korea.
Headquarters8 Chungjeong-ro, Seodaemun-gu, Seoul (Chong Kun Dang Building). Tel. +82-2-6373-0600
Exchange / tickerKorea Exchange, KOSPI: 001630
ISINKR7001630000 (standard KRX format for code 001630; confirm against the KRX register before use)
CUSIPNot applicable (no US listing)
Fiscal year end31 December (FY2025 was the company's 71st fiscal period)
Share capitalKRW 12,525 million at par value KRW 2,500. This implies about 5.01 million issued shares; about 4.76 million shares are outstanding excluding treasury stock.
Employees (holding company, standalone)37 (S&P Global, latest); 35 (June 2026, TheVC).
Employees (group context)Chong Kun Dang (associate): about 2,346 (2025). Kyongbo Pharm: 575 (March 2026). CKD Healthcare: about 330.
Auditor—
Market capitalisationAbout KRW 178–183 bn (KRW 37,350 at 6 October 2026 on 4.76m outstanding shares, S&P Global; KRW 182.9 bn on issued-share basis, Butler)
CEOChoi Hee-nam, Representative Director (since 28 March 2024)
Chairman / controlling shareholderLee Jang-han (33.73% direct stake)
Websitewww.ckd-holdings.com

CKD Holdings is the pure holding company at the apex of the Chong Kun Dang Group, one of South Korea's oldest pharmaceutical groups. The listed entity reports consolidated revenue of about KRW 959 bn (FY2025). Almost all of it comes from three healthcare subsidiaries:

CKD Healthcare: (51%-owned, unlisted): consumer health functional foods. Its Lacto-Fit probiotic franchise made it the group's largest consolidated revenue line.

Kyongbo Pharm: (43.41%, KOSPI): synthetic APIs and finished generics, now pivoting into antibody-drug conjugate (ADC) contract manufacturing.

CKD Bio: (about 39%, KOSPI): fermentation APIs, probiotics and botulinum toxin.

The group's flagship prescription-drug company, Chong Kun Dang Pharmaceutical (26.70%, KOSPI: 185750; FY2025 revenue KRW 1.69 tn), is equity-accounted rather than consolidated. A large share of the holding company's intrinsic value therefore sits outside its reported revenue line.

The shares trade at a deep holding-company discount: about 0.2–0.3x book value and a price-to-earnings ratio of about 3–4x. Owner-family succession is actively under way, and this shapes capital allocation.


What the Company Does

CKD Holdings is a pure holding company (순수지주회사) under Korea's Monopoly Regulation and Fair Trade Act. Its own business activities are:

  • Owning and managing equity stakes in group companies.

  • Collecting brand royalties, dividends, rental and service fees.

  • Allocating capital, including stake purchases in subsidiaries and new investments.

In March 2024 it added investment-related business purposes to its articles of incorporation. These cover investing in new-technology businesses, start-ups and SMEs, establishing new-technology finance subsidiaries, and accelerator activities. The change signals an intent to act as an investor, not only a passive parent (Dailypharm, 29 February 2024).

Company's Own Description

CategoryAffiliates
HealthcareChong Kun Dang, CKD Bio, Kyongbo Pharm, CKD Healthcare
Real-estate leasingCKD Industry
Construction / environmentBell E&C
Services / transportBell SM (a family-owned affiliate, not a holding-company subsidiary)
Marketing solutionsBell Communications
ITBell I&S

On its corporate website the company presents itself as follows:

  • It was launched in November 2013 when Chong Kun Dang converted to a holding-company structure to pursue a new leap as a global pharmaceutical group.

  • Its role is to maximise the value of operating companies, led by Chong Kun Dang, by concentrating on new business development and new investment.

  • It aims to find future growth engines and build a sustainable management system.

The website lists its business line as "holding business and management consulting." It groups affiliates into six categories:

Digital Daily (media) was added in 2025.

Independent Characterisation

Economically, CKD Holdings is best understood as three businesses plus an equity stake.

  1. A consumer-health company (CKD Healthcare). It carries the consolidated income statement. It generated about 41% of consolidated revenue in Q2 2026. Profitability swings with marketing intensity in a saturated, promotion-heavy Korean supplements market.

  2. A B2B active-ingredient manufacturer (Kyongbo Pharm and CKD Bio). Together these generated about 43% of Q2 2026 revenue. They sell synthetic and fermentation APIs to domestic and international drugmakers, including the group's own Chong Kun Dang. Both are adding higher-value platforms: ADC CDMO at Kyongbo and botulinum toxin at CKD Bio.

  3. Group services and property. CKD Industry's real-estate leasing plus advertising, IT, construction and media affiliates generated about 14% of revenue. Holding-company royalty and fee income added about 2%.

  4. A 26.70% equity stake in Chong Kun Dang Pharmaceutical. Chong Kun Dang is a top-tier Korean prescription-drug marketer and developer. It is accounted for by the equity method, so it appears as share of profit and long-term investments rather than revenue. Equity-method gains were about KRW 21.6 bn in FY2025 and KRW 21.8 bn in FY2024 (S&P Global cash-flow data).

Revenue Model Mix

Revenue typeMain sourceApproximate weight (Q2 2026, % of consolidated revenue)
Product sales – consumer (health functional foods, cosmetics)CKD Healthcare~41%
Product sales – B2B APIs and finished genericsKyongbo Pharm~28%
Product sales – fermentation APIs, probiotics, toxinCKD Bio~15%
Services / leasing / advertising / IT / mediaCKD Industry and others~14%
Brand royalty, fees, rent, dividends (holding-company level)CKD Holdings standalone~2%

Source: Butler segment split (Q2 2026). Subscription or licensing revenue at consolidated level is negligible. Milestone and licence income such as the Novartis CKD-510 milestones accrues at Chong Kun Dang, the equity-accounted associate.

Value-Chain Position, Customers and End-Markets

BusinessValue-chain positionMain customers / channelsEnd-markets
CKD HealthcareBranded consumer products, with own plant at DangjinHome shopping (29.8% of supplement sales in 2023, down from 42.2% in 2021), online, own mall, retail (including a past Daiso entry), agency networkKorean consumer health and wellness
Kyongbo PharmUpstream API synthesis plus finished-dose generics; ADC CDMO under constructionDomestic pharma (including Chong Kun Dang), export API customers, hospitals and pharmacies for finished productsAntibiotics (cephalosporins), cardiovascular (atorvastatin), analgesics; ADC developers
CKD BioUpstream fermentation API; probiotic raw materials and contract manufacturing; aesthetic toxinGlobal and domestic drugmakers; health-food brands; aesthetic clinicsTransplant immunosuppression, anti-infectives, probiotics, aesthetics
CKD Industry and othersReal-estate leasing, group servicesGroup companies and third partiesProperty, advertising, IT, media

Strategy

Stated Strategy Themes

These are paraphrased from company disclosures and the AGM.

  1. Maximise operating-company value through new business development and new investment. The holding company frames its role as finding growth engines and building a sustainable management system (corporate website).

  2. Responsible management and objective performance evaluation of subsidiaries. The aim is fast, specialised decision-making by business line, group synergy, and higher corporate and shareholder value (company statement on the June 2026 bond).

  3. Strengthen control of subsidiaries. Stake purchases are explicitly tied to raising dividend income and brand-royalty revenue (company statement, June 2026).

  4. ESG integration. Targets 2050 carbon neutrality, supply-chain ESG management and fair-trade compliance, under eight material issues (Sustainability Report 2022/2023).

Initiatives in the Last 24 Months

InitiativeEntityDateDetail / target
Investment-holding capabilityCKD HoldingsMarch 2024 onwardNew investment business purposes; M&A-experienced director appointed
Digital, AI and media diversificationCKD HoldingsNovember 2024; August 2025D-Tribe acquisition; Digital Daily (KRW 20 bn) to build digital and AI insight for pharma
Subsidiary stake build-upCKD Holdings2023–2028About KRW 10 bn a year of stake purchases planned through 2028; KRW 30 bn earmarked from the June 2026 bond
Debt refinancing and term-outCKD HoldingsJune 2026KRW 77 bn bond: KRW 32 bn 2-year and KRW 45 bn 3-year. First dual-tranche issue.
ADC CDMO build-outKyongbo Pharm2024–2027Asan ADC GMP plant (KRW 96 bn). Target of KRW 1 tn ADC CDMO revenue by 2033. Government projects: KRW 16.9 bn MOTIE ADC project (2025) and AI autonomous-lab project (KRW 2.4 bn grant to Kyongbo within KRW 19.2 bn total, to December 2029).
Toxin commercialisation and globalisationCKD Bio2025–2027Korean launch (July 2025); China filing after Phase 3; US Phase 1; halal positioning
Profit-first restructuringCKD Healthcare2025–2026Marketing efficiency and own-mall focus. FY2025 operating income KRW 32.3 bn; H1 2026 margin 9.8%.
Large-scale bio R&D campusChong Kun Dang (associate)2025–2033Baegot complex (KRW 2.2 tn total); KRW 1 tn Woori Bank financing agreement (May 2026); KRW 61.1 bn exchangeable bond (September 2025); public bonds
NRDO and R&D reorganisationChong Kun Dang (associate)October 2025; mid-2026Archela (CKD-508, CKD-514, CKD-513); Neurateon (formulation and technology research subsidiary); CKD USA
Obesity and blockbuster co-promotionChong Kun Dang (associate)October 2025 onwardWegovy co-promotion (about KRW 48.8 bn in Q1 2026 per analyst estimate); Evenity; Eylea

Medium-Term Financial Targets and Guidance

EntityTarget
KyongboKRW 1 tn ADC CDMO revenue by 2033
CKD HealthcareDouble-digit operating margin by 2027

CKD Holdings does not publish consolidated financial guidance. Subsidiary-level targets are:

Chong Kun Dang's CEO guided qualitatively at the March 2026 AGM: timely new launches, product competitiveness and market responsiveness to deliver solid profit growth.

Products & Services

CKD Healthcare (Health Functional Foods, Foods, Cosmetics)

Product / brandDescriptionTarget customerLaunch / statusPricing model
Lacto-Fit (락토핏) SaengyusangyunPowder-stick probiotic line in age- and gender-specific variants (Gold, Core, Kids, Bebe, Beauty). Korea's market-leading probiotic by share. Accounted for nearly 60% of company sales at Q4 2019.Mass market, all ages2016 launch; continuous line extensionsConsumer retail (not disclosed)
Drinkable Lacto-Fit (Original, Apple)Probiotic yoghurt drinksConvenience-oriented consumersLaunched 2024Retail
Aikeo (아이커)Children's growth / height-support supplementParents of childrenAward-winning product since 2016Retail
Promega (프로메가)Omega-3 (EPA/DHA) rangeAdults, cardiovascular healthOngoingRetail
Im-Vita (아임비타)Multivitamin rangeAdultsOngoingRetail
Dr.Care Dang Coach ZeroNutritional formula for diabetic patientsDiabetic consumers2,024Retail
GL-Fit Diet; Diet CoachBody-fat-reduction probiotic; weight-control formulaWeight-management consumers2,024Retail
Berberine productBlood-glucose-management supplementMetabolic-health consumersLaunched 2025–2026 (Dailypharm)Retail
Red ginseng and other health foodsPart of a stated 100+ SKU rangeGifting and seniorsOngoingRetail
Bellasu; Contramark CreamCosmetics brandsBeauty consumersNovember 2017Retail

Stated medium-term goal ("Beyond Healthcare 1-2-3" by 2027):

  1. Become Korea's number-one health functional food company.

  2. Achieve a double-digit operating margin.

  3. Lead in three domains: supplements, cosmetics and food.

Kyongbo Pharm (APIs, Finished Dose, ADC CDMO)

Product / serviceDescriptionCustomerStatus
Cephalosporin APIs (e.g., ceftizoxime, ceftriaxone)Synthetic antibiotic APIsDomestic and export drugmakersCore legacy line
Atorvastatin APICardiovascular APIDomestic and export drugmakersCore legacy line
Maxigesic (맥시제식)Combination analgesic (finished product)Hospitals and pharmaciesRecent launch; main growth driver of finished-dose sales
Finished generics (e.g., Eldocorp capsule, Janustin tablet, Dapacan tablet)23 products under licence-revocation litigation, about KRW 13.5 bn annual sales (5.1–5.65% of revenue)Hospitals and pharmaciesAt risk after the August 2026 first-instance loss; appeal and stay applications planned
ADC CDMO (Asan ADC GMP plant)Covers preclinical, clinical and commercial supply of ADC drug substance and drug product. In-house linker and payload development.Biotech and pharma ADC developers (MOUs with Binex, Protium Science, Pharosgen)Plant under construction; investment KRW 96 bn; target of KRW 1 tn revenue by 2033 (company statement, June 2025)

CKD Bio (Fermentation APIs, Probiotics, Toxin)

Product / serviceDescriptionCustomerStatus
Immunosuppressant APIsFermentation-derived transplant immunosuppressantsGlobal and domestic drugmakersCore. The API segment is 84% of CKD Bio revenue (Q2 2026).
Antibiotic APIsFermentation-derived anti-infectivesGlobal and domestic drugmakersCore
Probiotics (raw material and finished CDMO)Strain supply and contract manufacturing. Formerly the Lacto-Fit OEM until CKD Healthcare in-sourced production in 2022.Health-food brands14% of revenue (Q2 2026)
Tyemvers 100U / 200U (티엠버스)Botulinum toxin type A for moderate-to-severe glabellar lines. Uses a licensed European strain registered on GenBank. Fully animal-free and HSA-free process. First toxin with Indonesian BPJPH halal certification (per company/press).Aesthetic clinics; Middle East and Southeast Asia targeted100U approved 31 March 2025; 200U approved 16 September 2025; domestic launch July 2025. China Phase 3 met non-inferiority versus Botox (74.0% vs 74.9% responders, January 2026); China filing planned. US IND cleared April 2025.
Microbiome CDMOContract servicesBiotechDevelopment stage

Other Consolidated Businesses

BusinessOffering
CKD IndustryReal-estate leasing
Bell CommunicationsTV and campaign advertising; handles major CKD Healthcare brands
D-TribeDigital and social-media marketing agency, founded 2001. Revenue KRW 0.41 bn post-acquisition, with an operating loss of KRW 0.27 bn.
Bell E&CConstruction and environment services
Bell I&SIT services
Digital DailyOnline IT/business news and database information. A Naver content partner. Equity of KRW 9.5 bn at end-2024.
CKD Holdings (standalone)Brand royalty, management fees, rental income

Associate: Chong Kun Dang Pharmaceutical (Equity-Accounted)

CategoryProducts
In-licensed / co-promoted blockbustersProlia and Evenity (Amgen, osteoporosis); Wegovy (Novo Nordisk, co-promotion from 1 October 2025); Prevenar (pneumococcal vaccine); Eylea (ophthalmology, recently launched); Godex (Celltrion Pharm); Fexuclu (Daewoong); Januvia (MSD). Atozet and Vytorin co-promotion with Organon has ended and Organon now sells them alone.
Own brandsDilatrend (hypertension); Gliatilin (cognitive); Telmi series (over KRW 50 bn in H1 2026); Benfobel-S (vitamin); Penzal (OTC analgesic); Lucenbiess (ranibizumab biosimilar); Neulapeg (neutropenia); Gitec (natural-product gastritis drug, in price negotiation)
AssetMechanism / indicationStatus
CKD-510HDAC6 inhibitorLicensed to Novartis as PKN605; global Phase 2 with completion expected in 2027; first post-deal milestone received
CKD-702EGFR × c-Met bispecific, NSCLCPhase 1 part 2
CKD-703c-Met ADCUS Phase 1; first patient dosed
CKD-339HypertensionMFDS Phase 3 IND, July 2026
CKD-508CETP inhibitorTransferred to Archela
CKD-514Oral GLP-1Transferred to Archela
CKD-513BBB-penetrant HDAC6 inhibitorTransferred to Archela
CKD-704 / CKD-706Biosimilars (dermatology / autoimmune)Development; CKD-706 EU Phase 1 planned

This is not consolidated revenue, but it is central to valuation.

Financial Detail

Peer Comparison

CompanyListingCKD Holdings stakeAccountingMain business

Chong Kun Dang Pharmaceutical

KOSPI 185750

26.70% (largest shareholder; owner group total 40.15%)

Equity method (associate)

Ethical drugs, OTC, R&D

CKD Healthcare (종근당건강)

Unlisted

51.0%

Consolidated

Health functional foods, cosmetics

Kyongbo Pharm (경보제약)

KOSPI 214390

43.41% (owner group total 60.55%)

Consolidated

Synthetic APIs, finished generics, ADC CDMO

CKD Bio (종근당바이오)

KOSPI 063160

About 39% (39.11% at March 2024)

Consolidated

Fermentation APIs, probiotics, botulinum toxin

CKD Industry (종근당산업)

Unlisted

—

Consolidated

Real-estate leasing

Bell Communications, Bell E&C, Bell I&S, D-Tribe

Unlisted

—

Consolidated (where controlled)

Advertising, construction/environment, IT, digital ads

Digital Daily

Unlisted

87.7%

Consolidated (from August 2025)

Online IT/business media

Bell SM

Unlisted

None (owned 40% by Lee Ju-won, 30% by Lee Jang-han, 15% each by two daughters)

Not consolidated (family affiliate)

Services and transport; holds a small CKD Holdings stake

Stake in Chong Kun Dang by Year

YearStake in Chong Kun Dang
201920.2%
202225.1%
202626.70%

Segment Overview

SegmentQ2 2026 share of revenue

CKD Healthcare

41%

Kyongbo Pharm

28%

CKD Bio

15%

CKD Industry & others

14%

Holding company

2%

Segment revenue (KRW Bn)

Segment revenue (KRW Bn)FY2023FY2024FY2025

CKD Healthcare revenue (KRW Bn)

458.1497.3472.4

Kyongbo Pharm revenue (KRW Bn)

216.4238.6264.1

CKD Bio revenue (KRW Bn)

160.4171.8160.1

CKD Holdings consolidated revenue (KRW Bn)

879.8957.8959.0

Segment operating income (KRW Bn)

Segment operating income (KRW Bn)FY2023FY2024FY2025

CKD Healthcare operating income (KRW Bn)

19.0-0.232.3

Kyongbo Pharm operating income (KRW Bn)

5.610.53.5

CKD Bio operating income (KRW Bn)

-20.211.03.6

CKD Holdings consolidated operating income (KRW Bn)

17.035.558.3

Segment Margins & Growth (%) and Revenue by Segment (%)

Segment metric (%)FY2023FY2024FY2025

CKD Healthcare operating margin (%)

4.10.06.8

Kyongbo Pharm operating margin (%)

2.64.41.3

CKD Bio operating margin (%)

-12.66.42.2

CKD Healthcare revenue growth YoY (%)

-12.58.6-5.0

Kyongbo Pharm revenue growth YoY (%)

3.710.310.7

CKD Bio revenue growth YoY (%)

2.87.1-6.8

CKD Healthcare share of consolidated revenue, pre-elimination (%)

52.151.949.3

Kyongbo Pharm share of consolidated revenue, pre-elimination (%)

24.624.927.5

CKD Bio share of consolidated revenue, pre-elimination (%)

18.217.916.7

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

926.0909.0879.8957.8959.0

Revenue growth YoY (%)

7.9-1.8-3.28.90.1

Gross profit (KRW Bn)

441.4399.2383.9444.6427.3

Operating income, company-reported (KRW Bn)

34.4-32.917.035.558.3

D&A (KRW Bn)

35.742.945.343.344.0

EBITDA, computed (KRW Bn)

70.110.062.378.8102.3

Net income incl. minorities (KRW Bn)

25.8-22.740.640.354.3

Net income attributable to owners (KRW Bn)

16.01.147.033.640.4

EPS basic, attributable (KRW)

3,2122199,7447,0598,493

EPS diluted (KRW)

3,2122199,7447,0598,493

Dividend per share (KRW)

——1,400—1,400

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin (%)

Margin (%)FY2021FY2022FY2023FY2024FY2025

Gross margin (%)

47.743.943.646.444.6

Operating margin (%)

3.7-3.61.93.76.1

EBITDA margin (%)

7.61.17.18.210.7

Net margin, total net income (%)

2.8-2.54.64.25.7

Net margin, attributable (%)

1.70.15.33.54.2

Balance Sheet and Per-Share Data

Balance-sheet itemFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

1,367.61,376.41,456.01,495.81,628.8

Cash & equivalents (KRW Bn)

79.935.945.229.480.3

Cash & short-term investments (KRW Bn)

144.982.881.261.1117.1

Short-term debt incl. current portion of LTD (KRW Bn)

179.0285.6390.3369.5480.3

Long-term debt (KRW Bn)

163.0141.372.1107.455.8

Total debt incl. leases (KRW Bn)

345.3429.3468.0479.7540.8

Net debt (KRW Bn)

200.4346.5386.9418.5423.7

Total equity incl. minorities (KRW Bn)

840.0798.5823.5849.8913.1

Equity attributable to owners (KRW Bn)

541.0528.9563.0587.5637.0

Minority interest (KRW Bn)

299.0269.7260.5262.3276.0

Goodwill & intangibles (KRW Bn)

25.529.427.331.443.9

Long-term investments incl. Chong Kun Dang stake (KRW Bn)

306.9337.3379.0393.5423.5

Inventory (KRW Bn)

175.9188.5194.8237.7224.2

Working capital (KRW Bn)

119.2-0.8-100.2-63.6-116.7

Book value per share (KRW)

109,358108,745118,253123,410133,813

Cash-flow item

Cash-flow itemFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

40.5-46.537.124.076.0

Capital expenditure (KRW Bn)

100.558.025.541.556.0

Free cash flow (KRW Bn)

-60.0-104.511.6-17.620.1

Cash acquisitions (KRW Bn)

0.00.08.6-0.118.3

Dividends paid, incl. to minorities (KRW Bn)

10.910.410.013.010.4

Share buybacks (KRW Bn)

4.35.15.30.00.0

Net debt issued (KRW Bn)

124.281.411.39.258.8

Cash interest paid (KRW Bn)

5.310.219.420.720.7

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

3.07-2.775.004.826.16

ROA (%)

1.64-1.500.751.502.31

ROIC (%)

3.20-3.011.342.853.69

Current ratio (x)

1.381.000.810.870.81

Debt / equity (x)

0.410.540.570.560.59

Net debt / EBITDA, S&P basis (x)

2.8634.436.215.314.17

Interest coverage, OP ÷ cash interest (x)

6.5-3.20.91.72.8

Asset turnover (x)

0.710.660.620.650.61

Cash conversion cycle, year-end basis (days)

120142150175173

Revenue History

Quarter (KRW Bn)RevenueYoYOperating incomeYoYNet income

Q1 2025

246.6-1.4%11.9-5.0%7.8

Q2 2025

242.2-2.5%16.5+92.7%11.4

Q3 2025

234.2+0.8%18.1+142.4%20.0

Q4 2025 (derived)

236.0—11.8——

Q1 2026

240.3-2.6%19.3+62.0%17.9

Q2 2026

251.2+3.7%6.6-59.8%17.6

Segment Overview — CKD Healthcare

SegmentDomestic vs. export exposure (qualitative)Evidence

CKD Healthcare

Predominantly domestic. Exported Lacto-Fit to China via cross-border channels in 2019–2020.

Daishin Securities (April 2020) noted Lacto-Fit export expansion to China. Current export share not disclosed.

Kyongbo Pharm

Mixed. API exports plus domestic API and finished-dose sales. ADC CDMO targets global clients.

API business described as facing Chinese and Indian competition. ADC CDMO strategy aims at the global market (Bizwatch, June 2025).

CKD Bio

Significant export exposure in APIs (immunosuppressants, antibiotics). Toxin to target China, the US, the Middle East and Southeast Asia.

NICE D&B and KIRS reports; China Phase 3 and US IND for Tyemvers

CKD Industry & others

Domestic

Real-estate and services affiliates

Share Price and Market Valuation

Price metricFY2021FY2022FY2023FY2024FY2025

Year-end share price, adjusted (KRW)

68,84248,90055,93646,36044,951

Year-end market cap (KRW Bn)

379.3258.2282.6227.1220.2

Return window

Return windowReturnBasis

Latest price

KRW 37,350 (6 October 2026)

S&P Global

1-year

About −17% to −21%

S&P Global (August 2026); Paasa

3-year

About −33%

vs. FY2023 year-end adjusted close (computed)

5-year

About −55%

Paasa

52-week range

KRW 36,000–55,600 (as of August 2026)

S&P Global

Beta

0.53

S&P Global

Valuation Multiples

MultipleFY2021FY2022FY2023FY2024FY2025

P/E (x)

23.72240.336.016.765.45

P/B (x)

0.450.320.340.270.24

EV/EBITDA (x)

12.3882.0815.0711.539.22

EV/Sales (x)

0.940.911.070.950.98

Dividend yield (%)

2.032.862.503.023.11

Valuation Snapshot

MultipleValue

P/E

3.42x

P/B

0.19x

EV/EBITDA

9.00x

EV/Sales

0.94x

Dividend yield

3.75%

Enterprise value

About KRW 904 bn (includes minority interests and net debt)

Credit Ratings

AgencyRatingOutlook

Domestic (Korea)

A+ (corporate bond, per Dealsite, June 2026; Korea Ratings analyst commentary cited)

Not specifically confirmed

Moody's / S&P / Fitch

Not rated

—

Capital Instruments

InstrumentAmount (KRW Bn)Maturity

Short-term borrowings (FY2025)

389.6

Within 1 year (rolling bank lines)

Current portion of long-term debt (FY2025)

90.7

Within 1 year; includes the bond refinanced in July 2026 (about KRW 32 bn)

Bond 4-1

32.0

About July 2028 (2-year)

Bond 4-2

45.0

About July 2029 (3-year)

Long-term debt, other (FY2025)

55.8—

Use Details

UseAmount

Refinancing

KRW 32 bn

Operating funds (SG&A, taxes, dividends)

KRW 15 bn

Subsidiary stake purchases and new investments

KRW 30 bn

Analyst Conclusions

Guidance and Expectations

CKD Holdings: No formal consolidated guidance. Only one broker covers the stock, so consensus growth forecasts are not meaningful.

Chong Kun Dang (associate): A May 2026 broker report forecasts associate operating income of about KRW 80 bn in 2026 and about KRW 78 bn in 2027 (separate basis). That implies flat equity-method income.

Credit view: Korea Ratings expects good earnings capacity centred on Chong Kun Dang and CKD Healthcare's margin recovery, with rising leverage from Baegot capex.

Bull Case

  1. Sum-of-the-parts dislocation. At its May 2026 market value of about KRW 1.1 tn, the 26.70% Chong Kun Dang stake is worth about KRW 295 bn. Add 43.41% of Kyongbo, about 39% of CKD Bio and 51% of CKD Healthcare (FY2025 operating income KRW 32.3 bn). Gross asset value comfortably exceeds the market cap of about KRW 180 bn, even after holding-level net debt.

  2. Durable earnings inflection at CKD Healthcare. H1 2026 operating income rose 54% to KRW 22.2 bn at a 9.8% margin, and the subsidiary targets double-digit margins by 2027. Consolidated operating income has risen from KRW −32.9 bn to KRW 58.3 bn in three years.

  3. Multiple optionality catalysts. Tyemvers China filing after positive Phase 3; Kyongbo ADC plant start-up; CKD-510 Phase 2 readout (2027) feeding associate value.

Bear Case

  1. Structural discount may be permanent. Succession is being executed through subsidiary-stake gifts, and media speculate on share swaps. Minority holders could see value transferred rather than unlocked. ROE of about 6% does not justify a re-rating on its own.

  2. Leverage and cash conversion. Net debt is about 4.2x EBITDA, short-term funding dominates, free cash flow is marginal (KRW 20.1 bn in FY2025), and ADC capex is rising. Associate Baegot spending may constrain dividends up the chain.

  3. Subsidiary execution risk. Kyongbo's licence loss and margin compression (Q2 2026 operating income KRW 0.9 bn). CKD Bio's recurring losses. Supplements market contraction. Q2 2026 consolidated operating income fell 60%.

Catalysts and Monitorables (Next 12 Months)

Expected timingCatalyst / monitorable
Mid-November 2026Q3 2026 results: test whether the Q2 profit dip was transitory
Late 2026 – 2027Kyongbo appeal and stay outcome on the 23 products
2,027Tyemvers China approval timeline; US Phase 1 progress
2026–2027Kyongbo ADC plant commissioning, GMP certification and first client contracts
2026–2027CKD Healthcare top-line stabilisation after the H1 2026 decline of 8.9%
OngoingFurther owner-family transactions at the holding-company level; any in-kind contribution or tender
OngoingChong Kun Dang: Wegovy run-rate, CKD-510 Phase 2 progress, CKD-703 data, Baegot capex pacing
March 2027FY2026 dividend decision (watch whether DPS rises above KRW 1,400)
OngoingHolding-company stake purchases (about KRW 10 bn a year) and use of bond proceeds

Analyst Verdict

CKD Holdings is a classic Korean family holding company. Reported earnings understate the underlying assets, and governance and leverage explain much of the discount.

On fundamentals, the past three years show real operational progress. Consolidated operating income rose from a KRW 32.9 bn loss in FY2022 to a KRW 58.3 bn profit in FY2025, driven mainly by CKD Healthcare's cost discipline. The shares trade at about 3–4x earnings and about 0.2–0.3x book. That is cheap even by Korean holding-company standards, and cheaper than Dong-A Socio or GC Holdings on price-to-book.

Three things temper the case. First, top-line growth has been close to zero for five years. The consolidated subsidiaries operate in contested markets: promotion-heavy supplements, commoditised APIs and a crowded toxin field. Second, the balance sheet carries about KRW 424 bn of net debt, mostly short-term, and free cash flow has been thin. Kyongbo's ADC build-out and the associate's KRW 2.2 tn Baegot campus will absorb cash for years. Third, the controlling family is moving through succession using subsidiary stakes. The chairman retains 33.73% of the holding company, so outside shareholders face uncertainty about how that last step will be executed and priced.

The Q2 2026 profit drop shows earnings remain fragile. So does the Kyongbo licence ruling. Neither is a balance-sheet threat at holding-company level.

On balance, the stock looks fundamentally undervalued on a sum-of-the-parts basis, but the catalysts to close that gap are largely outside minority shareholders' control. Investors should treat it as a value position with a long holding period, sized for governance risk. The key signposts are:

  1. Sustained double-digit margins at CKD Healthcare.

  2. Tangible ADC contracts at Kyongbo.

  3. China approval for Tyemvers.

  4. A transparent, minority-friendly succession structure.

  5. Any step-up in shareholder returns beyond the static KRW 1,400 dividend.

Absent progress on items 4 and 5, the discount is likely to persist even as operating results improve.


Principal Sources

CategorySources
CompanyCKD Holdings corporate website (company overview, affiliate list)
Financial dataS&P Global Market Intelligence via StockAnalysis (income statement, balance sheet, cash flow, ratios; data to Q2 2026); Butler (DART summaries, segment mix); ETFShopping (quarterly DART results, ownership); Paasa; Craft; Simply Wall St; ROIC.ai
AGM disclosuresMedifonews and Dailypharm (26 March 2026; 28 March 2024)
Credit and bondsDealsite (24 June 2026), Dailypharm (26 June 2026), SBS Biz (26 June 2026), Korea Financial News (19 June 2026)
Ownership and successionDailypharm (29 August 2026; 7 August 2025; 7 January 2025), Medical Times (10 October 2026), The Fact (31 August 2026), Dealsite (9 September 2025), HuffPost Korea / C-Journal (2026)
SubsidiariesDailypharm (CKD Healthcare: 23 March 2026, 8 September 2026, 21 November 2025, 25 March 2025; Kyongbo: 24 January 2025, 28 August 2026; CKD Bio toxin: 1 April 2025), Dealsite (12 June 2025), MoneyToday (6 November 2025), Bizwatch (24 June 2025), MTN (27 March 2025; 20 May 2026), Asia Economy (20 January 2026), Digital Today (16 September 2025), Toyo Economy (14 July 2025)
Chong Kun Dang (associate)Dealsite (2 February 2026; 31 July 2026), Bizwatch (2 February 2026), Dailypharm (20 March 2026), CEO Score Daily (12 June 2026), Insight (13 July 2026), Toyo Economy (12 July 2026; 14 September 2026), Medifonews (18 September 2025), broker reports (Eugene, Kiwoom, May 2026 broker note)
PeersDealsite (Dong-A Socio, 9 February 2026), Butler (GC Holdings), AlphaDistill (Huons Global, GC Holdings), Meritz (Hanmi Pharm)
Market dataKorea Health Functional Food Association via fnnews, Metro and MTN; IMARC Group; IQVIA via Bizwatch
HistoryDailypharm (11 April 2011), Kormedi (7 February 2023), Medical Times (7 February 2013), Insight

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground

Lee Jang-han (이장한), age 74

Chairman; controlling shareholder (33.73%)

Group chairman since the 1990s, after the founder's death in 1993

Son of founder Lee Jong-geun.

Choi Hee-nam (최희남), age about 66

CEO / Representative Director, inside director

Since 28 March 2024

BA and MA in Economics (Hanyang University); PhD in Economics (University of Pittsburgh). IMF Executive Director (2016); CEO of Korea Investment Corporation (2018); Chairman of the Board of SC First Bank (from 2022); Milken Institute Global Fellow. Compensation not disclosed individually.

Lee Hee-jae (이희재), age about 55

Inside director (M&A / investment)

Since 28 March 2024

EMBA (Kellogg–HKUST). Goldman Sachs, Deutsche Bank, J.P. Morgan (MD, M&A advisory), Yulchon law firm (M&A adviser), CJ Corp. EVP and head of M&A (from 2020).

Na Seung-yong (나승용)

Outside director

Re-elected 26 March 2026

Former President, Mirae Asset Global Investments

Jo Jeong-hee (조정희)

Outside director

Re-elected 26 March 2026

Managing partner, D'Code law firm

Jo Jung-yong (조중용)

Standing auditor

Re-elected 28 March 2024

Full-time statutory auditor

Governance Detail

CompanyCEOSinceBackground

Chong Kun Dang (associate)

Kim Young-joo, President and CEO

2015; re-elected March 2024

Also chairs the Chong Kun Dang board

CKD Bio

Park Wan-gap

March 2024

Hanyang University chemistry (BSc, MSc). Joined Kyongbo in 2010; API sales head from 2022.

Kyongbo Pharm

Kim Tae-young, President

—

Former CKD Holdings CEO

CKD Healthcare

Jung Soo-chul

May 2025

First leadership change in 14 years

Archela (Chong Kun Dang subsidiary)

Dr Lee Ju-hee

October 2025

Seoul National University PhD; MSKCC postdoc; ex-Chong Kun Dang research

Board & Management Changes

DateChange

28 March 2024

Choi Hee-nam appointed CEO; Lee Hee-jae added to the board; Kim Tae-young not re-nominated.

May 2025

Jung Soo-chul appointed CEO of CKD Healthcare.

26 March 2026

Outside directors Na Seung-yong and Jo Jeong-hee re-elected. At Chong Kun Dang, Lee Kyu-woong re-elected and Kwon Yu-kyung newly elected as inside directors; Lee Woo-ram (ex-Samil PwC) appointed standing auditor.

Major Shareholders

HolderStake in CKD HoldingsSource / date

Lee Jang-han

33.73%

Dailypharm, August 2026

Largest shareholder plus related parties (total)

48.09%

Change-in-holdings report, 8 June 2026. This was 46.02% in November 2021 and 45.98% in early 2021.

Bell SM (family-controlled affiliate)

12,569 shares (about 0.25%) at April 2025; buying continued into 2025

Dailypharm, August 2025

Treasury shares

About 0.25m shares (about 5% of issued); KRW 16.3 bn at cost

S&P Global balance sheet

5%-holder report filed 30 September 2026

Filer not identified in sources reviewed

DART filing list (Butler)

Competitive Landscape

Peer Comparison FY2025

PeerFY2025 revenue (KRW Bn)FY2025 OP marginNotes

GC Holdings (005250)

2,451.51.5%

Net loss in FY2025. P/B about 0.54–0.77x.

Dong-A Socio Holdings (000640)

1,429.86.8%

Revenue +7.2%. Announced absorption of Dong-A Pharm. P/B about 0.5x.

Huons Global (084110)

847.510.7%

Revenue +4.2%

Peer Comparison FY2025 — Revenue

Metric (FY2025)CKD HoldingsDong-A Socio HoldingsGC HoldingsHuons Global

Revenue (KRW Bn)

959.01,429.82,451.5847.5

Revenue growth YoY (%)

0.17.211.24.2

Operating margin (%)

6.16.81.510.7

R&D intensity (% of revenue)

2.8———

P/B (x, latest available)

0.190.500.54—

Company Snapshot

$674.9M

Revenue

575

Employees

1941

Founded

SWOT Analysis

Strengths

  • Leading consumer brand. Lacto-Fit built CKD Healthcare from about KRW 81 bn of revenue (2016) to KRW 595.4 bn (2021). It reached about 60% of company sales at its peak.
  • Proven turnaround capacity. CKD Healthcare's operating income went from KRW −0.2 bn (FY2024) to KRW 32.3 bn (FY2025), and to KRW 22.2 bn in H1 2026 alone (9.8% margin).
  • Consolidated margin recovery. Operating margin rose from −3.6% (FY2022) to 6.1% (FY2025) as SG&A fell by KRW 71 bn.
  • Strong credit-market franchise. The KRW 60 bn bond drew KRW 213 bn of orders and was priced 3–4 bp inside the A+ curve (June 2026).
  • Valuable equity stake. The 26.70% stake in Chong Kun Dang (market cap about KRW 1.1 tn in May 2026) is worth about KRW 295 bn at that value (computed). That alone exceeds CKD Holdings' entire market cap of about KRW 180 bn.
  • Differentiated toxin asset. Tyemvers met non-inferiority to Botox in a 553-patient China Phase 3. It is animal-free and HSA-free, with halal certification.

Weaknesses

  • Stagnant top line. FY2021–25 revenue CAGR is about 0.9%.
  • Low returns. ROE is 6.2% and ROIC 3.7% (FY2025), well below the cost of capital.
  • Leverage and liquidity. Net debt is KRW 423.7 bn, about 4.2x EBITDA. The current ratio is 0.81x, and short-term borrowings of KRW 389.6 bn dominate the debt stack.
  • Weak cash conversion. Free cash flow was negative in three of the last five years (FY2021: KRW −60.0 bn; FY2022: KRW −104.5 bn).
  • Unprofitable or marginal subsidiaries. CKD Bio posted a net loss in FY2025 (KRW −2.9 bn) and an operating loss in Q2 2026 (KRW −5.0 bn). Kyongbo's FY2025 operating margin was 1.3%.
  • Low R&D intensity at consolidated level. About 2.8% of revenue, versus about 9–12% at the associate.

Opportunities

  • Kyongbo ADC CDMO. KRW 96 bn plant; partnerships with Binex, Protium and Pharosgen; KRW 1 tn 2033 revenue ambition.
  • Tyemvers China approval. Phase 3 complete. Hugel is the only Korean toxin already approved there.
  • Associate upside from CKD-510. Novartis Phase 2 is expected to complete in 2027 and Novartis lists it as a core cardiovascular, renal and metabolic asset. Associate profit flows through equity-method income.
  • Obesity co-promotion. Wegovy contributed about KRW 48.8 bn of associate revenue in Q1 2026 (analyst estimate).
  • Re-rating via governance. Korea's "value-up" reforms and the possible resolution of succession could narrow a P/B discount of about 0.2–0.3x.
  • Digital and media capability. Digital Daily and D-Tribe could reduce third-party marketing costs at CKD Healthcare (management rationale, August 2025).

Threats

  • Kyongbo licence revocation. First-instance loss on 27 August 2026 puts about KRW 13.5 bn of annual sales (about 5% of Kyongbo revenue) at risk if stays lapse.
  • Supplements market contraction. Market down from KRW 6.14 tn (2022) to about KRW 6.04 tn (2024, estimate). CKD Healthcare revenue fell 8.9% in H1 2026.
  • Drug-price erosion at the associate. Prolia patent expiry (April 2025) and Gliatilin reimbursement change (October 2025).
  • Associate capex burden. The KRW 2.2 tn Baegot programme could depress equity-method income and dividends. Korea Ratings expects group net debt/EBITDA to rise to about 2.5x in 2026–27.
  • Succession-related conflicts. Media speculate on share swaps that could transfer value between listed subsidiaries and the holding company.
  • Toxin competition. 17 domestic licensees; Daewoong and Medytox also pursuing China.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Mar / 1 Apr 2025CKD Bio's Tyemvers 100U receives MFDS approval (glabellar lines)First in-house toxin approval; entry into the aesthetics market
Apr 2025Tyemvers receives US FDA IND clearance for Phase 1Path to US registration
Apr 2025Chong Kun Dang's Prolia loses patent protection; price cut followsPressure on the associate's top product
May 2025Jung Soo-chul named CEO of CKD HealthcareStart of the profit-first turnaround
12 Jun 2025Daejeon Regional FDA revokes licences for 23 Kyongbo products (about KRW 13.5 bn sales) for shipments during a suspension period and pre-expiry stockingRegulatory and compliance risk at a listed subsidiary
18 Jun / 9 Jul 2025Court grants interim and then full stays of the revocationSales continue pending trial
Jun 2025Chong Kun Dang acquires Baegot land (KRW 94.9 bn) and signs MOU with Siheung for a KRW 2.2 tn bio complexLargest investment in the group's history
Jul 2025Tyemvers 100U begins domestic supply; first allocation done in AprilCommercial launch
29 Jul / 29 Aug 2025CKD Holdings acquires 87.7% of Digital Daily for KRW 20 bnDiversification; criticised by some as non-core
14 Aug 2025Q2 2025 results: revenue KRW 242.2 bn (−2.5%), operating income KRW 16.5 bn (+92.7%)Margin recovery
8–9 Sep 2025Chairman and spouse gift all Kyongbo shares to three children (eldest son to 6.21%)Succession step
16 Sep 2025Tyemvers 200U approvedPortfolio expansion
18 Sep 2025Chong Kun Dang signs Wegovy co-promotion (from 1 October)Obesity growth driver for the associate
30 Sep 2025Chong Kun Dang issues a KRW 61.1 bn exchangeable bond over treasury shares to fund BaegotFunding without new debt-heavy borrowing
20 Oct 2025Chong Kun Dang launches NRDO subsidiary Archela (CKD-508, CKD-514, CKD-513)R&D restructuring
Nov 2025Chong Kun Dang returns to the public bond market (target KRW 100–150 bn)Baegot funding
6 Nov 2025Kyongbo selected for MOTIE AI autonomous-lab project (to December 2029)ADC technology
14 Nov 2025Q3 2025: revenue KRW 234.2 bn (+0.8%), operating income KRW 18.1 bn (+142.4%), net income KRW 20.0 bn (+431.7%)Peak quarterly profitability
19–20 Jan 2026CKDB-501A China Phase 3 shows non-inferiority to Botox; CKD Bio shares rise more than 20% intradayChina filing catalyst
2 Feb 2026Chong Kun Dang FY2025: record revenue KRW 1.692 tn (+6.7%); operating income KRW 80.6 bn (−19%)Associate earnings pressured by R&D
18 Mar 2026CKD Holdings FY2025 business report filedAnnual disclosure
23 Mar 2026CKD Healthcare FY2025 operating income of KRW 32.3 bn disclosed, best since 2020Turnaround confirmed
26 Mar 2026CKD Holdings 71st AGM: FY2025 revenue KRW 959.0 bn, operating income KRW 58.3 bn (+64.2%); DPS KRW 1,400; outside directors re-electedShareholder return maintained
May 2026Kyongbo ADC plant investment raised from KRW 85.5 bn to KRW 96 bn; Chong Kun Dang signs KRW 1 tn Woori Bank facilityCapex step-up
15 May 2026Q1 2026: revenue KRW 240.3 bn (−2.6%), operating income KRW 19.3 bn (+62%), net income KRW 17.9 bn (+128%)Strong start
11 Jun 2026Chong Kun Dang approves KRW 392.5 bn Baegot facility investment (to August 2028)Capex intensity for the associate
24–26 Jun 2026CKD Holdings bond book-building draws KRW 213 bn of orders for KRW 60 bn; upsized to KRW 77 bn; priced 3–4 bp below rating curve (A+)Strong credit-market access
Jul 2026Organon takes Atozet and Vytorin sales in-house, ending its collaboration with Chong Kun DangPortfolio churn
27 Jul 2026CKD Holdings discloses MFDS Phase 3 IND approval for Chong Kun Dang's CKD-339 (hypertension)Late-stage pipeline
31 Jul 2026Chong Kun Dang Q2 2026 (separate): revenue KRW 475.4 bn (+10.7%), operating income KRW 19.9 bn (−10.1%)Wegovy and Evenity drive the top line; R&D weighs on profit
14 Aug 2026CKD Holdings Q2 2026: revenue KRW 251.2 bn (+3.7%), operating income KRW 6.6 bn (−59.8%), net income KRW 17.6 bnProfit setback from Kyongbo and CKD Bio
27–28 Aug 2026Kyongbo loses first-instance suit over the 23 licence revocations; appeal and stay applications plannedUp to about 5% revenue at risk
28 Aug / 2 Oct 2026Lee Jang-han gifts his entire 9.55% Chong Kun Dang stake to three children; Lee Ju-won becomes second-largest shareholderSuccession advances; holding-company stake untouched
31 Aug / 30 Sep 2026CKD Holdings files amended reports on the subsidiary business suspension (Kyongbo)Ongoing regulatory disclosure
8 Sep 2026CKD Healthcare H1 2026 operating income KRW 22.2 bn (+54%) on revenue KRW 226.1 bn (−8.9%)Margin-over-volume strategy working
10 Sep 2026Chong Kun Dang's Baegot knowledge-industry centre passes building and traffic review (conditional)Construction progress
30 Sep 20265%-holder (large shareholding) report filed on CKD HoldingsOwnership change to monitor
12 Oct 2026Amended H1 2026 report filedDisclosure housekeeping

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: CKD Healthcare revenue rose from KRW 458.1 Bn in FY2023 to KRW 472.4 Bn in FY2025.
Chong Kun Dang Holdings Corp. — Revenue by Segment
Series (KRW Bn)FY2023FY2024FY2025
CKD Healthcare revenue458.1497.3472.4
Kyongbo Pharm revenue216.4238.6264.1
CKD Bio revenue160.4171.8160.1
CKD Holdings consolidated revenue879.8957.8959

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.